Quick Overview
- Amphenol shares declined 6.29% as investors took profits after a robust earnings-driven rally
- First quarter 2026 earnings per share reached $1.06 versus analyst expectations of $0.95; revenue totaled $7.62B against $7.08B forecasts
- Analyst firms Wall Street Zen and Zacks shifted their ratings to “Hold” from “Buy”
- Chief Executive Richard Norwitt offloaded more than 515,000 shares during February, generating approximately $75.9M
- Street consensus price target holds at $176.53 with 13 analysts rating Buy and 2 rating Hold
Shares of Amphenol (APH) tumbled 6.29% during Friday’s trading session, starting the day at $127.72, as market participants retreated following a sustained upward move.
The decline seems driven primarily by profit-taking dynamics rather than fundamental deterioration in the company’s operational outlook. APH had experienced notable momentum leading into its quarterly report, prompting some traders to secure gains.
The company’s first quarter 2026 performance proved impressive. Earnings per share landed at $1.06, surpassing the Street consensus of $0.95. Total revenue hit $7.62 billion, considerably exceeding the anticipated $7.08 billion — representing a year-over-year surge of 58.4%.
Looking ahead to Q2 2026, management projected EPS between $1.14 and $1.16. Wall Street currently anticipates full-year earnings per share of $4.76.
Despite exceeding expectations, market participants appear to be reassessing whether the stock’s current price adequately reflects its growth trajectory. APH currently commands a price-to-earnings multiple of 36.70 alongside a PEG ratio of 1.20.
Rating Cuts Contribute to Selling Pressure
Wall Street Zen adjusted its stance on APH from “Buy” to “Hold” over the weekend. Zacks implemented an identical downgrade in March, pointing to valuation considerations.
However, the overall analyst consensus remains constructive. Among 15 firms tracking the stock, 13 maintain Buy recommendations while only 2 suggest Hold. The average price objective stands at $176.53.
Evercore boosted its price target to $180 with an “Outperform” designation following the earnings release. Truist demonstrated even greater confidence, increasing its target to $200 while maintaining a “Buy” call. Barclays similarly preserved its “Overweight” stance with a $180 price objective.
Executive Share Sales Raise Questions
Chief Executive Richard Adam Norwitt divested 515,281 shares throughout February at a mean price of $147.27, generating proceeds near $75.9 million. This transaction reduced his direct holdings by 21.09%.
Collectively, company insiders have liquidated 646,056 shares during the past 90 days — representing approximately $94.6 million in total value.
While executive stock sales don’t necessarily indicate underlying problems, the magnitude and timing of these transactions have captured investor attention.
Institutional investors maintain significant exposure, holding 97.01% of outstanding shares. Multiple smaller investment firms established new stakes during Q4 2025 and Q1 2026, albeit at relatively modest position sizes.
An additional consideration affecting market sentiment: a recent senior notes offering has elevated the company’s debt-to-equity ratio to 1.18. While not particularly concerning, this metric has prompted increased scrutiny of the balance sheet among certain investors.
The stock’s 52-week trading band extends from $80.32 to $167.04. The 50-day moving average currently rests at $137.31, while the 200-day average sits at $139.35 — both positioned above the current trading level.
APH maintains a year-to-date advance of 1.30%, and technical indicators continue signaling a Buy. The company’s regular quarterly dividend payment remains intact.
